Form 8-K - Current report:
SEC Accession No. 0001193125-24-244201
Filing Date
2024-10-25
Accepted
2024-10-25 16:59:28
Documents
16
Period of Report
2024-10-24
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d842130d8k.htm   iXBRL 8-K 34104
2 EX-99.1 d842130dex991.htm EX-99.1 20607
6 GRAPHIC g842130g14n45.jpg GRAPHIC 4799
7 GRAPHIC g842130g50s05.jpg GRAPHIC 11948
  Complete submission text file 0001193125-24-244201.txt   210688

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ntla-20241024.xsd EX-101.SCH 2849
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20241024_lab.xml EX-101.LAB 17996
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20241024_pre.xml EX-101.PRE 11261
18 EXTRACTED XBRL INSTANCE DOCUMENT d842130d8k_htm.xml XML 3630
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 241397706
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)